Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41375-020-01018-y http://scihub22266oqcxt.onion/10.1038/s41375-020-01018-y 32814839!7437386!32814839     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Leukemia 2021 ; 35 (4): 1121-1133 Nephropedia Template TP {{tp|p=32814839|t=2021. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study |pdf=|usr=}}{{32814839}} gab.com Text Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study JO: Leukemia http://www.kidney.de/pget.php?&tw=1&pmid=32814839 #FOAvip Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation </= 93% in air and/or PaO2/FiO2 ratio </= 300 mmHg. Median age was 80.5 years, and 85.3% had >/= 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of >/=2 points in the ordinal scale was 82.4% (95% confidence interval, 71-93). Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with PaO2/FiO2 < 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19. Twit Text FOAVip Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study ????Leukemia http://www.kidney.de/pget.php?&tw=1&pmid=32814839 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32814839 #FOAvip English Wikipedia <ref>{{Cite pmid|32814839}}</ref> Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study #MMPMID32814839 Vannucchi AM; Sordi B; Morettini A; Nozzoli C; Poggesi L; Pieralli F; Bartoloni A; Atanasio A; Miselli F; Paoli C; Loscocco GG; Fanelli A; Para O; Berni A; Tassinari I; Zammarchi L; Maggi L; Mazzoni A; Scotti V; Falchetti G; Malandrino D; Luise F; Millotti G; Bencini S; Capone M; Piccinni MP; Annunziato F; Guglielmelli P Leukemia 2021[Apr]; 35 (4): 1121-1133 PMID32814839show ga Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation /= 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of >/=2 points in the ordinal scale was 82.4% (95% confidence interval, 71-93). Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with PaO2/FiO2 < 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19. |*COVID-19 Drug Treatment[MESH] |*Compassionate Use Trials[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Biomarkers[MESH] |COVID-19/diagnosis/metabolism/*virology[MESH] |Combined Modality Therapy[MESH] |Comorbidity[MESH] |Female[MESH] |Humans[MESH] |Janus Kinase 1/*antagonists & inhibitors[MESH] |Janus Kinase 2/*antagonists & inhibitors[MESH] |Janus Kinase Inhibitors/pharmacology/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Nitriles[MESH] |Prospective Studies[MESH] |Pyrazoles/pharmacology/therapeutic use[MESH] |Pyrimidines[MESH] |SARS-CoV-2/*drug effects[MESH] |Severity of Illness Index[MESH] |Treatment Outcome[MESH]Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19:(epmc).pdf DeepDyve Pubget Overpricing